DOCSLIB.ORG

Efficacy and Safety of Infliximab for Steroid‑Resistant Immune‑Related Adverse Events: a Retrospective Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Efficacy and Safety of Infliximab for Steroid‑Resistant Immune‑Related Adverse Events: a Retrospective Study MOLECULAR AND CLINICAL ONCOLOGY 14: 65, 2021 Efficacy and safety of Infliximab for steroid‑resistant immune‑related adverse events: A retrospective study YUKIO KADOKAWA1, MARI TAKAGI1, TOMOE YOSHIDA1, AKITOSHI TATSUMI2, KEIKO FUJITA1, TAKAKO INOUE3, SHUICHI OHE4, YASUTOMO NAKAI5, SACHIKO YAMAMOTO6, TOMOYUKI OTSUKA7, RYU ISHIHARA6, TAIKI ISEI4, TORU KUMAGAI3, KAZUO NISHIMURA5 and FUMIO IMAMURA7 1Department of Pharmacy, Osaka International Cancer Institute, Osaka Prefectural Hospital Organization, Osaka 541‑8567; 2Education and Research Center for Clinical Pharmacy, Kobe Pharmaceutical University, Kobe, Hyogo 658‑8558; Departments of 3Respiratory Medicine, 4Dermatologic Oncology, 5Urology, 6Gastroenterology and 7Medical Oncology, Osaka International Cancer Institute, Osaka Prefectural Hospital Organization, Osaka 541‑8567, Japan Received April 6, 2020; Accepted January 12, 2021 DOI: 10.3892/mco.2021.2227 Abstract. The present study investigated outcomes of grade 0 after a median of 18 (range, 9‑32) days. No AEs were infliximab (IFX) treatment among 8 Japanese patients with attributable to IFX. Additionally, anti‑cytomegalovirus (CMV) various types of cancer (4 with malignant melanoma, 3 with and antibacterial agents were administered in parallel given lung cancer and 1 with renal cancer) who developed severe the presence of CMV and Clostridium difficile (CD) infections steroid‑resistant immune‑related adverse events (irAEs) in in all patients, except in 1 exhibiting a marked IFX response association with immune checkpoint inhibitors (ICIs) to after one dose. The combination of highly immunosuppressive determine its efficacy and safety. Information, including IFX and high‑dose systemic steroid administration over a long patient background, treatment progress, examination data and period presumably predisposed the patients to opportunistic imaging data, was collected retrospectively from electronic enteric infections. Accordingly, early initiation of IFX medical records. Adverse reactions were evaluated using treatment in conjunction with systemic steroid therapy should the Common Terminology Criteria for Adverse Events be considered for severe diarrhea/colitis and other irAEs. version 4.0. Specific ICIs used were anti‑PD‑1, anti‑PD‑L1 However, the possibility for CMV and CD infections should and anti‑CTLA‑4 antibody preparations in 7, 2 and 5 patients, be recognized, and for these the treatment strategy may need respectively. Specific irAEs included grade 3 diarrhea/colitis to be modified at an early stage. in 7 patients and disseminated intravascular coagulation and myocarditis attributed to autoimmune activation in 1 patient. Introduction The median duration between systemic steroid and IFX treatments was 9 (range, 2‑39) days. A total of 3 patients Immune checkpoint inhibitors (ICIs) are promising drugs responded to IFX, 1 of whom responded after one dose and that can potentiate the immune system of cancer patients for 2 responded after two doses. Respective diseases improved to disease treatment. ICIs block endogenous factors, such as cytotoxic T‑lymphocyte antigen‑4 (CTLA‑4) and programmed cell death‑1 (PD‑1), thereby enhancing the antitumor effect. ICIs, such as nivolumab (Nivo), have reportedly extended the Correspondence to: Mr. Yukio Kadokawa, Department of patient overall survival in cases of different types of cancer Pharmacy, Osaka International Cancer Institute, Osaka Prefectural and have been approved in several countries. Meanwhile, Hospital Organization, 3‑1‑69 Otemae, Chuo‑ku, Osaka 541‑8567, Immune‑related adverse events (irAEs), which often occur Japan in association with immune checkpoint inhibitor (ICI) treat‑ E‑mail: [email protected] ment, require early detection and appropriate management considering their potentially fatal outcomes. Among irAEs, Abbreviations: CD, Clostridium difficile; ICI, immune checkpoint diarrhea/colitis occurs particularly frequently, and serious inhibitor; IFX, infliximab; irAEs, immune‑related adverse events; CMV, cytomegalovirus; CTLA‑4, T‑lymphocyte antigen‑4; PD‑1, complications, such as intestinal perforation, may follow programmed cell death‑1; PD‑L1, programmed cell death‑ligand 1; unless timely and appropriate treatment is provided (1). The PSL, prednisolone; IPI, ipilimumab; Nivo, nivolumab; CRT, American Society of Clinical Oncology guideline includes chemoradiation therapy; TNF‑α, tumor necrosis factor‑α; CyA, an organ system‑based management algorithm showing cyclosporine recommended management procedures for various irAEs according to grade (2). In line with this, steroid therapy with Key words: infliximab, immune‑related adverse event, immune approximately 1 mg/kg/day prednisolone (PSL) equivalent is checkpoint inhibitor, diarrhea/colitis, steroid resistance immediately initiated for grade 3 diarrhea/colitis. However, when symptoms do not improve, infliximab (IFX) treat‑ ment, generally at a dose of 5 mg/kg/day according to the 2 KADOKAWA et al: IFX FOR STEROID‑RESISTANT irAEs administration for ulcerative colitis (3‑11), has been recom‑ Results mended. Single‑dose IFX administration has often been selected as an irAE treatment, with additional doses admin‑ Background and irAE treatment details. Patient background istered only when no improvements occur after the first dose. and irAE treatment details are summarized in Table I. Six male Perez‑Ruiz et al (12) have demonstrated that the inhibition of and two female patients, with a median (range) age and body tumor necrosis factor‑α (TNF‑α) after ICI administration may weight of 66 (58‑74) years and 60.0 (38.0‑85.1) kg, respec‑ prevent the occurrence of severe colitis. IFX, approved in 1999 tively, were included in this study. Four patients presented in the United States and in 2003 in Japan, is an anti‑TNF‑α with malignant melanoma, three with lung cancer, and one antibody drug that binds to and neutralizes the action of with kidney cancer. Specific ICIs used included anti‑PD‑1, TNF‑α, which plays a key role in the development and exac‑ anti‑PD‑L1, and anti‑CTLA‑4 antibody preparations in seven, erbation of rheumatoid arthritis. While transient headache and two, and five patients, respectively. nausea can occur as short‑term adverse reactions to IFX, these irAE treatment was switched from steroids to IFX since symptoms are mild. However, it is imperative to pre‑emptively systemic steroid treatment was ineffective for grade ≥3 diar‑ identify symptoms of medium‑ and long‑term adverse reac‑ rhea/colitis (case nos. 1‑7) or for disseminated intravascular tions such as infectious diseases, demyelinating diseases, coagulation and myocarditis resulting from activated autoim‑ aplastic anemia, malignant tumors, autoimmune diseases, and munity (case no. 8). Grade 3 diarrhea/colitis occurred at a heart failure, among which infectious diseases are of partic‑ median (range) of 119 (5‑1,011) days after the first ICI dose or ular concern. Several case reports have described successful at a median (range) of 15.5 (5‑75) days after the last ICI dose. treatment of steroid‑resistant ICI‑induced diarrhea/colitis with Grade 3 hepatitis preceded diarrhea/colitis in one case IFX in patients receiving ipilimumab (IPI), an anti‑cytotoxic (case no. 4). T‑lymphocyte antigen‑4 (CTLA‑4) antibody preparation (3‑6), Three patients who responded to IFX satisfied the defined as well as anti‑programmed cell death‑1 (PD‑1) antibody or resolution (case nos. 1, 5 and 8). Accordingly, responses to anti‑programmed cell death‑ligand 1 (PD‑L1) antibody prepa‑ IFX occurred after one dose in case no. 1 and after two doses rations (7‑11). However, we were unable to identify any report in case nos. 5 and 8 (in case no. 5, an accessory third dose systematically dealing with the required number of IFX doses was administered, but the defined resolution was satisfied or the time to switch to after treatment. after two IFX doses). Although the treatment was transiently Therefore, this study investigated the outcomes of IFX effective in one case (case no. 2), irAEs relapsed. Two patients treatment among Japanese cancer patients who developed did not respond to IFX (case nos. 3 and 4), while two patients severe steroid‑resistant irAEs induced by various ICIs and (case nos. 6 and 7) underwent rapid deterioration of their examined its efficacy and safety for severe steroid‑resistant general condition after IFX treatment initiation and died irAEs. before the IFX effect was noted. The cause of death was irAE diarrhea and multi‑organ failure in case no. 6 and respiratory Materials and methods failure due to multiple lung metastases and pulmonary conges‑ tion in case no. 7. No causal relationships were observed Patients. Among nine Japanese patients with cancer who between IFX treatment and deaths. The median (range) underwent IFX treatment for ICI‑induced steroid‑resistant number of days between systemic steroid treatment and IFX irAEs at the Osaka International Cancer Institute (hereinafter initiation was 9 (2‑39) days. In three IFX responders, resolu‑ referred to as the ‘Institution’) between January 2018 and tion to grade 0 required a median (range) of 18 (9‑32) days June 2019, eight whose electronic medical records contained after IFX treatment initiation. No AEs were attributable the necessary treatment information were included; one patient to IFX. No patients developed cytomegalovirus (CMV) or who participated in a clinical trial was excluded. Clostridium difficile (CD) infection when grade 3 irAEs We obtained ‘consent to the publication of a paper related
Load more

Recommended publications
  • Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
    Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami) Media Release Copenhagen, Denmark and Lausanne, Switzerland, October 30, 2020 • ADC Therapeutics to continue the development and commercialization of Cami • Genmab to receive mid-to-high single-digit tiered royalty Genmab A/S (Nasdaq: GMAB) and ADC Therapeutics SA (NYSE: ADCT) today announced that they have executed an amended agreement for ADC Therapeutics to continue the development and commercialization of camidanlumab tesirine (Cami). The parties first entered into a collaboration and license agreement in June 2013 for the development of Cami, an antibody drug conjugate (ADC) which combines Genmab’s HuMax®-TAC antibody targeting CD25 with ADC Therapeutics’ highly potent pyrrolobenzodiazepine (PBD) warhead technology. Under the terms of the 2013 agreement, the parties were to determine the path forward for continued development and commercialization of Cami upon completion of a Phase 1a/b clinical trial. ADC Therapeutics previously announced that Cami achieved an overall response rate of 86.5%, including a complete response rate of 48.6%, in Hodgkin lymphoma patients in this trial who had received a median of five prior lines of therapy. Cami is currently being evaluated in a 100-patient pivotal Phase 2 clinical trial intended to support the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). The trial is more than 50 percent enrolled and ADC Therapeutics anticipates reporting interim results in the first half of 2021. “We have a long-standing relationship with the ADC Therapeutics team and believe they are an ideal partner for the ongoing development and potential commercialization of Cami,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
    [Show full text]
  • ADC Therapeutics SA (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ADC Therapeutics SA Date: February 4, 2021 By: /s/ Michael Forer Name: Michael Forer Title: Executive Vice President & General Counsel EXHIBIT INDEX Exhibit No. Description 99.1 Press release dated February 4, 2021 Exhibit 99.1 ADC Therapeutics Completes Enrollment in Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma Interim results anticipated in the first half of 2021 LAUSANNE, Switzerland, February 4, 2021 – ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced completion of enrollment in the pivotal Phase 2 clinical trial evaluating the efficacy and safety of camidanlumab tesirine (Cami, formerly ADCT-301) in patients with relapsed or refractory Hodgkin lymphoma.
    [Show full text]
  • ADC Therapeutics SA (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2020. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ADC Therapeutics SA Date: July 6, 2020 By: /s/ Dominique Graz Name: Dominique Graz Title: General Counsel EXHIBIT INDEX Exhibit No. Description 99.1 Press release dated July 6, 2020 Exhibit 99.1 ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine Lausanne, Switzerland — July 6, 2020 — ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology, today announced that the U.S.
    [Show full text]
  • Comparative Effectiveness of Pembrolizumab Vs. Nivolumab In
    www.nature.com/scientificreports OPEN Comparative efectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC Pengfei Cui1,2,4, Ruixin Li2,4, Ziwei Huang3,2,4, Zhaozhen Wu3,2, Haitao Tao2, Sujie Zhang2 & Yi Hu1,2,3* The efcacies of pembrolizumab and nivolumab have never been directly compared in a real-world study. Therefore, we sought to retrospectively evaluate the objective response rate (ORR) and the progression-free survival (PFS) of patients with recurrent or advanced non-small cell lung cancer (NSCLC) in a real-world setting. This study included patients with recurrent or advanced NSCLC diagnosed between September 1, 2015 and August 31, 2019, who were treated with programmed cell death 1 (PD-1) inhibitors at the Cancer Center of the Chinese People’s Liberation Army. PFS was estimated for each treatment group using Kaplan–Meier curves and log-rank tests. The multivariate analysis of PFS was performed with Cox proportional hazards regression models. A total of 255 patients with advanced or recurrent NSCLC treated with PD-1 inhibitors were identifed. The ORR was signifcantly higher in the pembrolizumab group than in the nivolumab group, while PFS was not signifcantly diferent between the two groups. Subgroup analysis showed that the ORR was signifcantly higher for pembrolizumab than for nivolumab in patients in the frst-line therapy subgroup and in those in the combination therapy as frst-line therapy subgroup. Survival analysis of patients receiving combination therapy as second- or further-line therapy showed that nivolumab had better efcacy than pembrolizumab. However, the multivariate analysis revealed no signifcant diference in PFS between patients treated with pembrolizumab and those treated with nivolumab regardless of the subgroup.
    [Show full text]
  • Cutaneous Adverse Effects of Biologic Medications
    REVIEW CME MOC Selena R. Pasadyn, BA Daniel Knabel, MD Anthony P. Fernandez, MD, PhD Christine B. Warren, MD, MS Cleveland Clinic Lerner College Department of Pathology Co-Medical Director of Continuing Medical Education; Department of Dermatology, Cleveland Clinic; of Medicine of Case Western and Department of Dermatology, W.D. Steck Chair of Clinical Dermatology; Director of Clinical Assistant Professor, Cleveland Clinic Reserve University, Cleveland, OH Cleveland Clinic Medical and Inpatient Dermatology; Departments of Lerner College of Medicine of Case Western Dermatology and Pathology, Cleveland Clinic; Assistant Reserve University, Cleveland, OH Clinical Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH Cutaneous adverse effects of biologic medications ABSTRACT iologic therapy encompasses an expo- B nentially expanding arena of medicine. Biologic therapies have become widely used but often As the name implies, biologic therapies are de- cause cutaneous adverse effects. The authors discuss the rived from living organisms and consist largely cutaneous adverse effects of tumor necrosis factor (TNF) of proteins, sugars, and nucleic acids. A clas- alpha inhibitors, epidermal growth factor receptor (EGFR) sic example of an early biologic medication is inhibitors, small-molecule tyrosine kinase inhibitors insulin. These therapies have revolutionized (TKIs), and cell surface-targeted monoclonal antibodies, medicine and offer targeted therapy for an including how to manage these reactions
    [Show full text]
  • 5.01.591 Immune Checkpoint Inhibitors
    MEDICAL POLICY – 5.01.591 Immune Checkpoint Inhibitors Effective Date: Sept. 1, 2021 RELATED POLICIES/GUIDELINES: Last Revised: Aug. 10, 2021 5.01.543 General Medical Necessity Criteria for Companion Diagnostics Related Replaces: N/A to Drug Approval 5.01.589 BRAF and MEK Inhibitors Select a hyperlink below to be directed to that section. POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | HISTORY ∞ Clicking this icon returns you to the hyperlinks menu above. Introduction Chemotherapy, often called chemo, is cancer treatment that uses drugs. Radiation and surgery treat one area of cancer. But chemo usually travels through the bloodstream to treat the whole body. Treating the whole body is called a systemic treatment. Immunotherapy is a new type of cancer treatment that helps the body’s immune cells fight the cancer more effectively. Cancer cells sometimes “hide” from the body’s cells that are designed to search for cells that don’t belong, like cancer cells or bacteria. Immune checkpoint inhibitors are drugs that block the way that cancer cells do this and so help the immune cells find them so they can be stopped. It is one of the ways we can make the environment less friendly to the cancer and slow its growth. Current immunotherapy drugs are complex molecules that must be given through a vein (intravenous). In the future, some may be given by a shot (injection) the patient could inject without help. This policy gives information about immunotherapy drugs and the criteria for when they may be medically necessary. Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria.
    [Show full text]
  • Chelsea & Westminster Healthcare Trust Drugs Committee
    Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group Summary of Main Points from the Meeting held on Monday 12th December 2016 2. Minutes and Summary Notes from last meeting The Minutes and Summary notes from the November 2016 Medicines Group meeting were approved and will be circulated. 3. Matters Arising The Group noted the matters arising from the previous meeting. 4. Business to be transacted by the Medicines Group 4.1 Formulary Applications Ex-panel Deferasirox (Exjade®) 90mg, 180mg and 360mg Tablets (Novartis) Exjade® film coated tablets have been introduced in November 2016. These will take the place of the dispersible tabs which will be phased out and no longer available from June 2017. Costs are equivalent to the dispersible tablets. The new film coated tablets have a number of advantages over the dispersible tablets including: - Can be swallowed whole - Lactose free - No food restrictions - No mixing/preparation required. Decision: Approved DuoResp Spiromax® 160 micrograms / 4.5 micrograms (Budesonide & Formoterol) Inhalation Powder (Teva) Request by the Respiratory Team for the management of asthma in line with the BTS guidelines where a ® combination of an inhaled long acting B2 agonist and corticosteroid is indicated. Adding DuoResp Spiromax to the formulary will provide an increased choice of devices available to prescribe. Symbicort Turbohaler® is already included on the formulary. DuoResp Spiromax® is more cost-effective than Symbicort Turbohaler® and is currently included on the NWLIF and GPs have already started to prescribe it. Decision: Approved Sodium Valpoate (Epilim Chronosphere®) 50mg and 100mg Modified Release Granules (Sanofi) Requested by the Paediatric Neurology Team for paediatric patients requiring sodium valpoate in very low doses.
    [Show full text]
  • Actemra® (Tocilizumab)
    Actemra® (tocilizumab) (Intravenous) Document Number: MODA-0002 Last Review Date: 10/26/2020 Date of Origin: 09/21/2010 Dates Reviewed: 12/2010, 03/2011, 05/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 09/2012, 11/2012, 12/2012, 03/2013, 06/2013, 09/2013, 11/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 05/2015, 09/2015, 12/0215, 03/2016, 06/2016, 09/2016, 12/2016, 03/2017, 05/2017, 09/2017, 12/2017, 03/2018, 06/2018, 10/2018, 10/2019, 10/2020, 11/2020 I. Length of Authorization Coverage will be provided as follows: o Castleman’s Disease: 4 months and may be renewed o Cytokine Release Syndrome: 4 doses only and may not be renewed o Immune Checkpoint Inhibitor related arthritis: 1 dose and may not be renewed o All other indications: 6 months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: o Actemra 80 mg/4 mL vial: 1 vial per 14 days o Actemra 200 mg/10 mL vial: 1 vial per 14 days o Actemra 400 mg/20 mL vial: 2 vials per 14 days B. Max Units (per dose and over time) [HCPCS Unit]: Diagnosis Billable Units Interval (days) Rheumatoid Arthritis & Polyarticular Juvenile Idiopathic 800 28 Arthritis, NMOSD Systemic Juvenile Idiopathic Arthritis, Castleman’s Disease (NHL) & Acute Graft Versus Host Disease 800 14 (aGVHD) Cytokine Release Syndrome (CRS) 3200 1 course of therapy only Immune Checkpoint Inhibitor related arthritis 800 1 course of therapy only III.
    [Show full text]
  • International Consensus Guidance for Management of Myasthenia Gravis 2020 Update
    VIEWS & REVIEWS OPEN ACCESS LEVEL OF RECOMMENDATION International Consensus Guidance for Management of Myasthenia Gravis 2020 Update Pushpa Narayanaswami, MBBS, DM, Donald B. Sanders, MD, Gil Wolfe, MD, Michael Benatar, MD, Correspondence Gabriel Cea, MD, Amelia Evoli, MD, Nils Erik Gilhus, MD, Isabel Illa, MD, Nancy L. Kuntz, MD, Janice Massey, MD, Dr. Narayanaswami Arthur Melms, MD, Hiroyuki Murai, MD, Michael Nicolle, MD, Jacqueline Palace, MD, David Richman, MD, and pnarayan@ Jan Verschuuren, MD bidmc.harvard.edu Neurology® 2021;96:114-122. doi:10.1212/WNL.0000000000011124 Abstract Objective To update the 2016 formal consensus-based guidance for the management of myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness method was used to develop consensus recommendations pertaining to 7 treatment topics. In February 2019, the international panel was reconvened with the addition of one member to represent South America. All previous recommendations were reviewed for currency, and new consensus recommendations were developed on topics that required inclusion or updates based on the recent literature. Up to 3 rounds of anonymous e-mail votes were used to reach consensus, with modifications to recommendations between rounds based on the panel input. A simple majority vote (80% of panel members voting “yes”) was used to approve minor changes in grammar and syntax to improve clarity. Results The previous recommendations for thymectomy were updated. New recommendations were developed for the use of rituximab, eculizumab, and methotrexate as well as for the following topics: early immunosuppression in ocular MG and MG associated with immune checkpoint inhibitor treatment.
    [Show full text]
  • Annex I Summary of Product Characteristics
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT YERVOY 5 mg/ml concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of concentrate contains 5 mg ipilimumab. One 10 ml vial contains 50 mg of ipilimumab. One 40 ml vial contains 200 mg of ipilimumab. Ipilimumab is a fully human anti-CTLA-4 monoclonal antibody (IgG1κ) produced in Chinese hamster ovary cells by recombinant DNA technology. Excipients with known effect: Each ml of concentrate contains 0.1 mmol sodium, which is 2.30 mg sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate). Clear to slightly opalescent, colourless to pale yellow liquid that may contain light (few) particulates and has a pH of 7.0 and an osmolarity of 260-300 mOsm/kg. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Melanoma YERVOY as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults, and adolescents 12 years of age and older (see section 4.4). YERVOY in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1). Renal cell carcinoma (RCC) YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).
    [Show full text]
  • Nivolumab in Metastatic Non–Small Cell Lung Cancer
    PRESCRIBER'S CORNER Section Editors: Christopher J. Campen and Beth Eaby-Sandy Nivolumab in Metastatic Non–Small Cell Lung Cancer ANDREA DEEL, PharmD From Kingsport Hematology Oncology, ung cancer is the leading NSCLC has led to the development of Kingsport, Tennessee cause of cancer deaths in agents that target specific molecular Author’s disclosures of potential conflicts of interest are found at the end of this article. the United States (Ameri- pathways in cancer cells (Kerr et al., Correspondence to: Andrea Deel, PharmD, can Cancer Society [ACS], 2014). Targeted therapies are a signifi- Kingsport Hematology Oncology, 4485 West L2015). Non–small cell lung cancer cant step forward in treating patients Stone Drive, Suite 200, Kingsport TN 37660. (NSCLC) is one of the most common with tumors that contain specific mu- E-mail: [email protected] types of the disease and accounts tations in these pathways. doi: 10.6004/jadpro.2016.7.2.7 for 85% to 90% of lung cancer cases In the United States, several agents © 2016 Harborside Press® (ACS, 2015). Nonsquamous NSCLC have been approved to target these accounts for approximately 45% to tumors. They include erlotinib, afa- 60% of all lung cancer cases, where- tinib (Gilotrif ), and gefitinib (Iressa), as squamous NSCLC accounts for which target EGFR signaling; crizo- approximately 25% to 30% of all lung tinib (Xalkori) and ceritinib (Zykadia), cancer cases (ACS, 2015). which target ALK rearrangements; Survival rates vary depending on bevacizumab (Avastin) and ramuci- the stage and type of the cancer and rumab (Cyramza), which target vascu- when it is diagnosed. For stage IV lar endothelial growth factor (VEGF) NSCLC, the 5-year survival rate is 1% signaling.
    [Show full text]
  • Antibody–Drug Conjugates: the Last Decade
    pharmaceuticals Review Antibody–Drug Conjugates: The Last Decade Nicolas Joubert 1,* , Alain Beck 2 , Charles Dumontet 3,4 and Caroline Denevault-Sabourin 1 1 GICC EA7501, Equipe IMT, Université de Tours, UFR des Sciences Pharmaceutiques, 31 Avenue Monge, 37200 Tours, France; [email protected] 2 Institut de Recherche Pierre Fabre, Centre d’Immunologie Pierre Fabre, 5 Avenue Napoléon III, 74160 Saint Julien en Genevois, France; [email protected] 3 Cancer Research Center of Lyon (CRCL), INSERM, 1052/CNRS 5286/UCBL, 69000 Lyon, France; [email protected] 4 Hospices Civils de Lyon, 69000 Lyon, France * Correspondence: [email protected] Received: 17 August 2020; Accepted: 10 September 2020; Published: 14 September 2020 Abstract: An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of. Keywords: antibody–drug conjugate; ADC; bioconjugation; linker; payload; cancer; resistance; combination therapies 1.
    [Show full text]